Compare GSK plc (GSK) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Star Bulk Carriers Corp — how do they compare? GSK plc trades at $52.66 (market cap $101.34B), while Star Bulk Carriers Corp trades at $26.56 (market cap $2.94B). The key difference: GSK plc is far larger — about 34.5× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (3.91%). Which is the better fit depends on your goals.
| GSK | SBLK | |
|---|---|---|
Market Cap | $101.34B | $2.94B |
Sector | Health | Industrials |
52-Week High | $61.18 | $28.21 |
52-Week Low | $36.20 | $16.79 |
Enterprise Value | $121.95B | $3.64B |
Dividend Yield | 3.49% | 3.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Star Bulk Carriers (SBLK) trades at $26.50, showing modest daily weakness with a 0.23% decline. The stock maintains a bullish technical outlook with strong moving average support, while recent earnings beats in Q4 2025 and Q1 2026 demonstrate operational strength. The company's modernizing fleet and dividend policy supporting yields above 10% provide attractive shareholder returns amid favorable dry bulk shipping rates.
SBLK presents compelling value with improving fundamentals and analyst optimism, though investors face risks from shipping rate volatility and cyclical industry exposure. The 58% buy rating consensus and projected profit margin expansion to 13% support upside potential, balanced by the need to monitor Q2 2026 earnings delivery against high expectations of $0.96 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
